SGLT-2 inhibitor, cardiovascular risk and outcome in patients with comorbidity of hypertension and diabetes [Cardiovascular disease]
Annals of Family Medicine
NOVEMBER 20, 2024
Sodium-glucose transporter 2 (SGLT-2) inhibitors have been proved to decrease the cardiovascular adverse events in several large randomized controlled trials (RCTS), but evidence limited to patients with type 2 diabetes and ASCVD. Population Studied individuals with comorbidity of hypertension and type 2 diabetes.
Let's personalize your content